Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK2838232 with Ritonavir in Healthy Subjects
NCT02795754Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2838232 in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by GSK. Primary endpoints: Number of participants with adverse events up to 10 weeks, Safety as assessed by hematology parameters up to 10 weeks and 17 more. Started Mar 2016; status: completed.
02
Drugs
GSK2838232
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02795754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795754.